subject area of
- Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries Journal Articles
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis Journal Articles
- Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada Journal Articles